CLAVULIN 200 28.5 MG / 5 ML
CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML · DIN 02238831 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is CLAVULIN 200?
CLAVULIN 200 28.5 MG / 5 ML contains CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02238831, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Jan-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLAVULIN 200 used for?
CLAVULIN is indicated for the treatment of infections caused by CLAVULIN-susceptible strains of designated bacteria such as Sinusitis, Otitis Media, Lower Respiratory Tract Infections, Skin and Soft Tissue Infections, and Urinary Tract Infections. It is also effective for infections caused by ampicillin (amoxicillin) susceptible organisms and mixed infections with both ampicillin-susceptible and β-lactamase producing organisms susceptible to CLAVULIN.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02238831 |
|---|---|
| Brand name | CLAVULIN 200 |
| Generic / active ingredient | CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 28.5 MG / 5 ML |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR |
| AHFS class | 08:12.16.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Jan-2003 |
| Original market date | 1998-10-29 00:00:00 |
How is it stored and handled?
reconstituted CLAVULIN - 125 F and CLAVULIN - 250F oral suspension should be stored under refrigeration (2°C to 8°C) and should be used within 10 days; reconstituted CLAVULIN - 200 and CLAVULIN - 400 oral suspension should be stored under refrigeration (2°C to 8°C) and should be used within 7 days
How is it supplied?
blister packs of 20 tablets (500F and 875 tablets); bottles of 100 mL (125F and 250F oral suspension); bottles of 70 mL (200 and 400 oral suspension)
Is AMOXICILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR. 28 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AMOXI CLAV | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510634 |
| AG-AMOXI CLAV | 875 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510642 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495910 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 1000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495929 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 2000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495937 |
| AMOXICILLIN/CLAV | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536021 |
| AMOXICILLIN/CLAV | 875 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536048 |
| APO-AMOXI CLAV | 125 MG | TABLET | APOTEX INC | MARKETED | DIN 02243350 |
| APO-AMOXI CLAV | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02243351 |
| APO-AMOXI CLAV | 875 MG | TABLET | APOTEX INC | MARKETED | DIN 02245623 |
Who else supplies AMOXICILLIN AND BETA-LACTAMASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR appears in 3391 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.